Targeting the progesterone receptor in breast cancer: mind the short form!

Thumbnail
View/Open
Date
2022-12-22
ICR Author
Author
Ronchi, C
Brisken, C
Type
Journal Article
Metadata
Show full item record
Abstract
The pre-surgical window of opportunity trial (WOT), MIPRA, provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist Mifepristone (RU486) may benefit patients with ER+ breast cancer characterized by a high ratio of PR-A versus PR-B isoform (>1.5) suggesting that PR may be targeted in a subset of patients.
URI
https://repository.icr.ac.uk/handle/internal/5722
DOI
Collections
Research team
Endocrine control mechans
Language
eng
Date accepted
2022-12-22
License start date
2022-12-22
Citation
Clinical Cancer Research, 2022, pp. CCR-22-3374 -
Publisher
American Association for Cancer Research (AACR)